AIM
CYTK icon

Aigen Investment Management’s Cytokinetics CYTK Stock Holding History

Aigen Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,216
Closed -$2.06M – 604
2026
Q1 		$2.06M Buy
31,216
+25,648
+461% +$1.63M 0.53% 48
2025
Q4 		$354K Buy
+5,568
New +$346K 0.08% 312
2024
Q3 		– Sell
-17,523
Closed -$949K – 787
2024
Q2 		$949K Buy
17,523
+6,870
+64% +$415K 0.18% 150
2024
Q1 		$747K Buy
+10,653
New +$824K 0.16% 193
2020
Q3 		– Sell
-46,412
Closed -$1.09M – 899
2020
Q2 		$1.09M Buy
46,412
+26,553
+134% +$498K 0.14% 234
2020
Q1 		$234K Buy
19,859
+851
+4% +$10.9K 0.03% 660
2019
Q4 		$202K Buy
+19,008
New +$195K 0.03% 549

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aigen Investment Management's CYTK Position: Q2 2026 in Review

Aigen Investment Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 31,216 shares — an estimated $2.06M sold.

Aigen Investment Management first reported a position in CYTK in Q4 2019 and held it in 7 quarters. The position peaked at $2.06M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Aigen Investment Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Aigen Investment Management sold 31,216 Cytokinetics shares in Q2 2026, an estimated $2.06M.
  • Aigen Investment Management first reported a position in Cytokinetics in Q4 2019 and held it in 7 quarters.
  • Aigen Investment Management's Cytokinetics position peaked at $2.06M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.